With Dexcom G7 CGM there are now even more reasons to recommend with confidence to your patients
Advertisement
Superior accuracy*,1
You can recommend with confidence knowing that Dexcom G7 is accurate and precise across all days of wear, rates of change, glucose levels (2.2 to 22.2 mmol/L) and ages (2+).2,3
It delivers an 8.2% adult MARD (back of arm)2, 8.1% paediatric MARD (back of arm)3 and a 95.3% repeatable precision in adults and children‡, ||,2,3
Proven performance2
Dexcom is the #1 clinically proven CGM,# and the most researched CGM now with over 300 registered clinical trials.** Dexcom real-time CGM has been shown to:
- Reduce HbA1c by 1% in T1D4
- Increase time in range by 14.2% for MDI users and 14.5% for CSII users5
Use of the Urgent Low Soon alert can reduce hypoglycaemia by 40%§,6
Powerfully simple
Dexcom G7 is a 60% smaller, all-in-one, discreet wearable with one-touch application.* It offers simple sensor insertion and a 30-minute warm up sensor time. When it comes to connectivity, G7 is the most connected CGM,## making it seamless to manage diabetes across various smart devices,†† health apps, and insulin delivery devices. You can also connect Direct to Apple Watch.††, ¶¶
It’s also reassuring to know that Dexcom G7 is waterproof for up to 2.4m when swimming, showering or exercising.||||
Plus so much more
Dexcom Clarity puts your patient’s care in one place. It simplifies access to patient glucose data, helping you identify relevant glucose patterns, insights and trends to support better-informed diabetes management decisions.^
Dexcom delivers demonstrated protection with a suite of features designed to prevent acute diabetes events such as hypoglycaemia, rebound hyperglycaemic episodes and DKA6-8, including;
- Urgent low alert
- Urgent Low Soon alert‡‡
- Delay First High alert‡‡
- Rising Fast / Falling Fast
- Customisable alerts
- Remote monitoring§§
Easy access through NDSS Subsidy for Australians living with Type 1 diabetes.***
Dexcom products meet the Minimum Standards for anzCGM Devices in Australia and New Zealand,9 demonstrating high standards of quality, accuracy and reliability2,3 in CGM. This high level of performance supports patient confidence and improved clinical outcomes.1
Dexcom customer service is ranked #9 on Forbes’ Best Customer Service list for 2026.10 Dexcom’s dedicated technical support team is available to provide reliable assistance and ensure a smooth experience for Dexcom customers.
We’re here to support you
Click here to request an educational sample.
Click here to learn more about how to support patients to trial Dexcom CGM, complete with a starter kit and follow-up from our team.
Dexcom offers simplified HCP education, resources and support through our Learning Management System amsl.learnupon.com.
CGM = Continuous Glucose Monitor; MARD = Mean Absolute Relative Difference; MDI = Multiple Daily Injection; CSII = Continuous Subcutaneous Insulin Infusion. *Compared to previous generations of Dexcom systems; ‡ Precision reflects the consistency of CGM measurements. It is evaluated using the %20/20 rule, ensuring CGM readings are within 1.1 mmol/L of the true value for levels below 3.9 mmol/L, and within 20% for levels above 3.9 mmol/L; Internet connection is required to send data to Dexcom Clarity. || Results obtained with sensors worn on the back of upper arm in patients age 7 and older; # Dexcom CGM systems have been studied in over 70 registered interventional clinical trials [clinicaltrials.gov]. Dexcom’s internal data on file, 2025. A copy of this data is available upon request; ** Based on comparison of completed trials registered at clinicaltrials.gov as of August 2026; § Severe hypoglycaemia < 3 mmol/L; ‡‡ Features unique to Dexcom CGM; §§ Separate Dexcom Follow app and internet connection required; ^ Internet connection is required to send data to Dexcom Clarity; †† Smart device sold separately. For a list of compatible smart devices, please visit www.dexcom.com/compatibility; ## Not all connections are available in Australia. To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/compatibility; ¶¶ Compatible smartphone is required to pair a new Dexcom G7 sensor with an Apple Watch. Dexcom G7 users must continuously have their smartphone within 10 metres to utilise the Share/Follow features. Apple Watch is not capable of Share/Follow. ^^ Separate Follow app and internet connection required; |||| Dexcom G7 and Dexcom ONE+ are waterproof for up to 2.4 meters for up to 24 hours; *** Subsidised for Australians living with Type 1 diabetes. Eligibility criteria applies. Visit ndss.com.au/cgm for more details.
References: 1Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7; 2 Garg SK, et al. Diabetes Technol Ther. 2022;24(6):373-80; 3 Laffel LM, et al. J Diabetes Sci Technol. 2023;17(4):962-7; 4 Beck RW, et al. JAMA. 2017;317(4):371-8; 5 Šoupal J, et al. Diabetes Care. 2020;43:37-43; 6 Puhr S, et al. Diabetes Technol Ther. 2019 Apr;21(4):155-158; 7 Mann EA, et al. Diabetes Care. 2025;48(5):768-775; 8. Acciaroli G, et al. J Diabetes Sci Technol. 2022;16(3):677-82; 9. Australian Diabetes Society et al. (2025) Strengthening Safety through Regulatory Standardisation for Continuous Glucose Monitoring Systems (anzCGM) in Australia and New Zealand. Available at: diabetessociety.com.au/guideline/strengthening-safety-through-regulatory-standardisation-for-contin… . Accessed 19 June 2026; 8 Mann EA, et al. Diabetes Care. 2025;48(5):768-775; 10. Forbes. (2025, October 14). Forbes best customer service companies 2026 list. forbes.com/lists/best-customer-service.
Dexcom, Dexcom G7, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2026 Dexcom, Inc. All rights reserved. Australasian Medical & Scientific Limited is a Dexcom company. MAT-xxxx Rev001 September 2026